Last reviewed · How we verify
ibuprofen Liquid-filled capsule
Ibuprofen liquid-filled capsules, marketed by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, hold a significant position in the over-the-counter pain relief market. A key strength is the product's unique liquid-filled capsule formulation, which may offer faster absorption and onset of action compared to traditional tablets. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | ibuprofen Liquid-filled capsule |
|---|---|
| Also known as | Commercial IBU |
| Sponsor | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects (PHASE1)
- Study of Acetaminophen (ACM) in Post-operative Dental Pain (PHASE3)
- Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: